Replimune Group Inc (REPL) is not a strong buy at the moment for a beginner investor with a long-term strategy. While there are some positive catalysts, the stock lacks significant momentum, and financial performance remains weak. It is better to wait for clearer signals or more favorable conditions.

Technical Analysis

The MACD is positive but contracting, indicating weakening momentum. The RSI is neutral at 38.214, and moving averages are converging, showing no clear trend. The stock is trading near its support level (S1: 7.438), with resistance at R1: 8.661.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Piper Sandler raised the price target to $14 and maintains an Overweight rating. The upcoming PDUFA date for RP1 on April 10 could act as a catalyst if the FDA decision is favorable.

Neutral/Negative Catalysts

The stock has been impacted by FDA-related uncertainties and lacks significant trading trends from hedge funds or insiders. Financial performance remains weak, with negative EPS and net income.

Financial Performance

In Q3 2026, revenue remained at 0 with no growth. Net income improved slightly YoY but is still negative at -$70.93M. EPS dropped to -0.77, down 2.53% YoY.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Piper Sandler raised the price target from $13 to $14 and maintains an Overweight rating. However, the approval decision for RP1 still carries risk, as noted by the firm.

7 Analyst Rating

Wall Street analysts forecast REPL stock price to rise

4 Buy

3 Hold

0 Sell

Moderate Buy

Current: 7.650

Low

Averages

11.43

High

Current: 7.650

Low

Averages

11.43

High

Piper Sandler

Overweight

maintain

$13 -> $14

AI Analysis

2026-02-05

Reason

Piper Sandler

Price Target

$13 -> $14

AI Analysis

2026-02-05

maintain

Overweight

Reason

Piper Sandler raised the firm's price target on Replimune to $14 from $13 and keeps an Overweight rating on the shares following Q3 reporting and ahead of RP1's April 10 PDUFA date. Replimune has felt the full brunt of the impact of FDA turmoil and seemingly capricious decision-making in recent months, Piper notes. The firm understands that additional analyses addressing FDA's concern around the contribution of components in the single-arm IGNYTE trial played a key role in this apparent about-face, and finds these recently disclosed analyses compelling. While Piper acknowledges that RP1's approval decision still carries risk, it's the firm's sense that FDA wouldn't have accepted the resubmission with the intent of rejecting it a second time.

BMO Capital

Evan Seigerman

Underperform

Market Perform

upgrade

$2 -> $11

2025-11-03

Reason

BMO Capital

Evan Seigerman

Price Target

$2 -> $11

2025-11-03

upgrade

Underperform

Market Perform

Reason

BMO Capital analyst Evan Seigerman upgraded Replimune to Market Perform from Underperform with a price target of $11, up from $2. The firm says current share levels "reflect appropriate risk" for the company's RP1 program. Replimune seems to have better alignment with regulators on a path forward for the drug, the analyst tells investors in a research note. BMO says Replimune's "productive" Type A meeting supports potential approval.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for REPL

Unlock Now

REPL Should I Buy

REPL Should I Buy

Should You Buy Replimune Group Inc (REPL) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch